Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans

被引:0
|
作者
Valdimarsson, H
Stefansson, M
Vikingsdottir, T
Arason, GJ
Koch, C
Thiel, S
Jensenius, JC
机构
[1] Univ Reykjavik, Dept Immunol, Reykjavik, Iceland
[2] Reg Hosp, Akureyri, Iceland
[3] Statens Serum Inst, DK-2300 Copenhagen, Denmark
[4] Univ Aarhus, Dept Med Microbiol & Immunol, Aarhus, Denmark
关键词
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mannan-binding lectin (MBL, previously named mannan-binding protein, MBP) is a serum collectin, which activates complement upon binding to microbial carbohydrates. This results in opsonization of the microorganisms as well as direct complement-mediated killing. Clinical evidence indicates that MBL has an important role in the innate immune defence against various pathogens. Genetically determined MBL deficiency is associated with increased susceptibility to infections. We have infused two MEL-deficient individuals with clinical grade MEL, purified from pooled donor plasma, in doses sufficient to attain normal concentration of MBL in serum. This resulted in normalization of complement-mediated opsonization. An initial rapid decrease in the serum concentration of MBL was followed by a slower decline with an estimated half-life of about 6 days. No adverse effects were observed and anti-MEL antibodies could not be detected following several MBL infusions. One of the two MBL recipient, a two-year-old girl, who had been suffering from repeated infections from the age of 4 months, was given a total of six MBL infusions. She has subsequently remained healthy for more than three years.
引用
收藏
页码:116 / 123
页数:8
相关论文
共 50 条
  • [1] Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans
    Valdimarsson, H
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 : 768 - 769
  • [2] Phase II study on mannan-binding lectin (MBL) substitution in MBL-deficient children with chemotherapy-induced neutropenia
    Brouwer, Nannette
    Frakking, Florine
    van Houdt, Michel
    Hart, Margreet
    Laursen, Inga
    Houen, Gunnar
    Budde, Ilona Kleine
    Strengers, Paul
    Dolman, Koert
    van de Wetering, Marianne
    Caron, Huib
    Kuijpers, Taco
    [J]. MOLECULAR IMMUNOLOGY, 2007, 44 (16) : 3944 - 3944
  • [3] On the quantification of Mannan-binding lectin (MBL)
    Frederiksen, PD
    Jensen, L
    Hansen, AG
    Matthiesen, F
    Thiel, S
    Turner, MW
    Jensenius, JC
    [J]. MOLECULAR IMMUNOLOGY, 2004, 41 (2-3) : 230 - 230
  • [4] Quantification of mannan-binding lectin (MBL)
    Frederiksen, P. D.
    Thiel, S.
    Jensenius, J. C.
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2007, 65 (06) : 596 - 596
  • [5] Biochemistry and genetics of mannan-binding lectin (MBL)
    Presanis, JS
    Kojima, M
    Sim, RB
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 : 748 - 752
  • [6] Recombinant mannan-binding lectin (MBL) for therapy
    Jensenius, JC
    Jensen, PH
    McGuire, K
    Larsen, JL
    Thiel, S
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2003, 31 : 763 - 767
  • [7] Increased Autoreactivity of Mannan-binding Lectin (MBL) in Diabetes
    Axelgaard, Esben
    Thiel, Steffen
    Ostergaard, Jakob A.
    Hansen, Troels K.
    [J]. DIABETES, 2016, 65 : A132 - A132
  • [8] Substitution of Mannan-Binding Lectin (MBL)-Deficient Serum With Recombinant MBL Results in the Formation of New MBL/MBL-Associated Serine Protease Complexes
    Keizer, Mischa P.
    Kamp, Angela
    van Mierlo, Gerard
    Kuijpers, Taco W.
    Wouters, Diana
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [9] Polymorphisms in Mannan-Binding Lectin (MBL)-Associated Serine Protease 2 Affect Stability, Binding to MBL, and Enzymatic Activity
    Thiel, Steffen
    Kolev, Martin
    Degn, Soren
    Steffensen, Rudi
    Hansen, Annette G.
    Ruseva, Marieta
    Jensenius, Jens C.
    [J]. JOURNAL OF IMMUNOLOGY, 2009, 182 (05): : 2939 - 2947
  • [10] Mannan-binding lectin (MBL) in women with tumours of the reproductive system
    St Jwierzko, A.
    Florczak, K.
    Cedzynski, M.
    Szemraj, J.
    Wydra, D.
    Bak-Romaniszyn, L.
    Emerich, J.
    Sulowska, Z.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (07) : 959 - 971